Key clinical point: A risk assessment protocol to guide choice of venous thromboembolism prophylaxis reduced risk of events without altering bleeding risk.
Major finding: The rate of pulmonary embolism (0.34% vs. 0.62%; P = .004) was significantly lower for those managed with the protocol.
Data source: A single-center prospective study.
Disclosures: Dr. Wylie reported a financial relationship with Arthrex.
Wylie J. AAOS 2020.